Remove Cardio Oncology Remove Obesity Remove Research
article thumbnail

Highlights of ACC 2024

Cardiology Update

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Investigators randomized 616 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=310) or placebo (n=306). New Engl J Med. April 6, 2024.